New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
05:38 EDTNVS, LLYEli Lilly acquires Novartis Animal Health for $5.4B in all-cash transaction
Eli Lilly (LLY) announced an agreement to acquire Novartis (NVS) Animal Health for approximately $5.4B in an all-cash transaction that will strengthen and diversify Lilly's own animal health business, Elanco. Upon completion of the acquisition, Elanco will be the second-largest animal health company in terms of global revenue, will solidify its number two ranking in the U.S., and improve its position in Europe and the rest of the world. Lilly will acquire Novartis Animal Health's nine manufacturing sites, six dedicated research and development facilities, a global commercial infrastructure with a portfolio of approximately 600 products, a robust pipeline with more than 40 projects in development, and an experienced team of more than 3,000 employees. Under the terms of the agreement, Lilly will acquire all assets of Novartis Animal Health for a total purchase price of approximately $5.4B, including anticipated tax benefits. Lilly plans to fund this acquisition with approximately $3.4B of cash-on-hand and $2B in debt to be issued. No other financial terms of the transaction are being disclosed. The transaction is expected to close by the end of 1Q15, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions. The transaction is not subject to any financing conditions.
News For LLY;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
11:02 EDTLLYEli Lilly granted FDA orphan status for treatment of sickle cell disease
Subscribe for More Information
08:35 EDTLLYEli Lilly reports final results of Phase III trial for Alimta
Eli Lilly announced final results of the Phase III PROCLAIM trial, a randomized, Phase III superiority study of patients with locally-advanced, nonsquamous non-small cell lung cancer, which evaluated Lilly's Alimta in combination with cisplatin with concurrent radiation followed by maintenance Alimta in comparison with etoposide and cisplatin plus concurrent radiation, followed by consolidation chemotherapy of the oncologist's choice. Those treated on the pemetrexed arm achieved a median overall survival of 26.8 months as compared to 25 months for those treated on the etoposide arm. Median progression-free survival was 11.4 months on the pemetrexed arm versus 9.8 months on the etoposide arm and an overall response rate of 35.9% on the pemetrexed arm and 33% on the etoposide arm.
08:09 EDTLLYEli Lilly to present data from several trials of Cyramza for cancer
Subscribe for More Information
May 27, 2015
08:32 EDTLLYEli Lilly's Humalog KwikPen approved by FDA
Subscribe for More Information
08:32 EDTNVSNovartis entered into collaboration with Rani Therapeutics, Reuters says
Subscribe for More Information
07:33 EDTNVSIncyte says clinical portfolio to be featured in 23 abstract presentations
Incyte Corporation (INCY) announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis (NVS) and independent investigators, will be presented at the 2015 American Society of Clinical Oncology and European Hematology Association annual meetings. These conferences will take place from May 29th – June 2nd in Chicago, IL and June 11th – 14th in Vienna, Austria. “The abstracts to be presented at ASCO and EHA showcase the depth and breadth of our development pipeline in oncology, as well as the success of our collaboration with Novartis,” stated Rich Levy, MD, Incyte’s Chief Drug Development Officer. “Incyte is committed to translating R&D excellence into new medicines which can improve patients’ lives, and these data, including novel:novel combinations from within our portfolio, provide further evidence of our ongoing progress.”
05:22 EDTNVSNovartis to present data on 21 medicines, 11 investigational compounds at ASCO
Subscribe for More Information
May 22, 2015
10:52 EDTLLY, NVSJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
08:39 EDTNVSNovartis initiates Phase 1 PCA062, triggering milestone payment to ImmunoGen
In a regulatory filing, ImmunoGen disclosed Novartis (NVS) Institutes for BioMedical Research notified ImmunoGen (IMGN) that Novartis had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing antibody-drug conjugate technology. Pursuant to the license taken under our 2010 Multi-Target Agreement, this start of clinical testing triggers a $5M milestone payment to ImmunoGen.
07:37 EDTLLYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
05:19 EDTNVSNovartis Afinitor extended PFS in Phase III trial in GI or lung origin NET
Novartis announced that the Phase III study of Afinitor tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors, or NET, of gastrointestinal, or GI, or lung origin met its primary endpoint: significant extension of progression-free survival, or PFS, compared to placebo plus best supportive care. The RADIANT-4 study is part of one of the largest clinical trial programs in NET.
May 20, 2015
11:36 EDTNVSNovartis says COPD programs met endpoints in Phase III study
Subscribe for More Information
May 19, 2015
08:57 EDTNVSLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:55 EDTNVSGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
12:29 EDTNVSCorium announces publication of data for needle-free transdermal flu vaccine
Corium International announced the publication of "promising" data on the use of its needle-free transdermal system to deliver influenza vaccine in the June 9 issue of Vaccine. The manuscript, entitled "Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs," details results of a preclinical study conducted by Novartis Vaccines (NVS) and Corium. The results demonstrate the compatibility of Corium's MicroCor needle-free transdermal system with cell culture-derived influenza vaccines, and establish its potential as a next-generation vaccine delivery system, the company said.
07:38 EDTNVSNovartis outlook has improved, says Bernstein
Subscribe for More Information
May 15, 2015
09:31 EDTNVSAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 14, 2015
09:22 EDTLLYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:44 EDTLLYInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
06:04 EDTLLYEli Lilly, Sanford-Burnham to investigate immunological therapies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use